Thrombocytopenia
Conditions
Interventions
Fondaparinux sodium group:Real world research does not intervene
Low molecular weight heparin:Real world research does not intervene
Sponsors
Tianjin People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. Patients with thrombocytopenia (30 x 10^9 / L < PLT < 100 x 10^9 / L); 3. Patients with anticoagulant indications; 4. Patients or legal representatives have been informed of the nature of the study and understand the provisions in the protocol to ensure compliance.
Exclusion criteria
Exclusion criteria: 1. Allergy to fondaparinux or contraindications; 2. High risk of bleeding: patients or history of hemorrhagic diseases, bleeding tendency, bleeding constitution or coagulation disorders; 3. Patients with hyperthyroidism, severe liver and kidney dysfunction and other anticoagulant drugs are contraindicated; 4. Patients may not comply with the study protocol (including the follow-up period), such as mental disorders, alcohol or drug use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 30 day bleeding events;30 day thrombosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| The occurrence time, development process, treatment measures, correlation and prognosis of adverse events with zeritol; | — |
Countries
China
Contacts
Public ContactYuejuan Cao
Tianjin People's Hospital
Outcome results
None listed